Graphite Bio, Inc. (GRPH)

NASDAQ: GRPH · IEX Real-Time Price · USD
8.67 -1.39 (-13.82%)
Jan 18, 2022 4:00 PM EST - Market closed
Market Cap503.54M
Revenue (ttm)n/a
Net Income (ttm)-115.37M
Shares Out58.08M
EPS (ttm)-7.05
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume543,158
Open9.88
Previous Close10.06
Day's Range8.60 - 10.05
52-Week Range8.11 - 34.00
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateNov 11, 2021

About GRPH

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency...

IndustryBiotechnology
IPO DateJun 25, 2021
Employees57
Stock ExchangeNASDAQ
Ticker SymbolGRPH
Full Company Profile

Financial Performance

Financial Statements

News

SomaLogic, Graphite Bio Make List of Most Promising Life Sciences Companies

Two public companies made the BioSpace list of the 30 most promising North American life sciences startups. SomaLogic Inc. ( SLGC , Financial) and Graphite Bio Inc. ( GRPH , Financial) are included in t...

Other symbols:SLGC
1 week ago - GuruFocus

Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sic...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #ASH21--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene i...

1 month ago - Business Wire

Graphite Bio to Host Key Opinion Leader Webinar on Gene Correction for Sickle Cell Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to tre...

1 month ago - Business Wire

Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted ...

2 months ago - Business Wire

Graphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to tre...

2 months ago - Business Wire

Graphite Bio Announces Presentation on Phase 1/2 CEDAR Trial of GPH101 in Sickle Cell Disease at Upcoming 63rd ASH An...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to tre...

2 months ago - Business Wire

Graphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to tre...

2 months ago - Business Wire

FMR LLC's Top 5 Buys in September

FMR LLC, the Boston-based asset management company commonly known as Fidelity, disclosed this month that its top-five trades during September included new buys in Toast Inc. ( TOST , Financial), Graphit...

Other symbols:ABSICLDXTOSTZI
3 months ago - GuruFocus

Graphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease at 49th Annual Sickle Cell Disease As...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted ...

3 months ago - Business Wire

Graphite Bio Announces Upcoming Presentation at 49th Annual Sickle Cell Disease Association of America National Conve...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted ...

3 months ago - Business Wire

Graphite Bio Announces Participation in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted ...

4 months ago - Business Wire

Graphite Bio Reports Recent Business Progress and Second Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing high-efficiency precision gene c...

5 months ago - Business Wire

Graphite Bio's Approach To Gene Editing Has BofA Securities and Morgan Stanley Bullish

A differentiated approach to gene editing has ushered a bullish sentiment from BofA Securities and Morgan Stanley on Graphite Bio, Inc. (NASDAQ:GRPH) just a few weeks after its IPO. BofA Securities on G...

5 months ago - Benzinga

Graphite Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purcha...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted ...

6 months ago - Business Wire

Sickle Cell Biotech, Graphite Bio Prices Upsized Initial Public Offering

Graphite Bio Inc (NASDAQ: GRPH) is set to go public on the heels of a $238 million raise less than ten months after getting started with a Series A funding of $45 million.  Graphite is using a familiar ...

6 months ago - Benzinga

Graphite Bio stock opens 30% above IPO price, pushes valuation above $1 billion

Graphite Bio Inc. received a warm reception on Wall Street, as the California-based gene-editing biotechnology company's stock opened 30% above its initial public offering price. The IPO priced overnigh...

6 months ago - Market Watch

Graphite Bio stock set to start trading as upsized IPO pricing values biotech at $926.1 million

Shares of Graphite Bio Inc. are set to start trading Friday, after the California-based gene-editing biotechnology company's upsized initial public offering priced at the top of the expected range. The ...

6 months ago - Market Watch

Graphite Bio Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure seri...

6 months ago - Business Wire